8-K: Personalis Q2 Revenue Falls 24%; Guidance Cut

Personalis, Inc. reported a 24% year-over-year revenue decline in Q2 2025 and lowered its full-year revenue guidance, despite strong clinical test volume growth.

Summary

• Total revenue for Q2 2025 was $17.2 million, a 24% decrease compared to $22.6 million in Q2 2024.
• Clinical test volume reached 3,478 in Q2 2025, marking a 59% sequential increase over Q1 2025.
• Gross margin for Q2 2025 was 27.6%, down from 35.6% in Q2 2024, primarily due to lower revenue volume, customer mix, and increased unreimbursed clinical test costs.
• Net loss for Q2 2025 was $20.1 million, compared to a net loss of $12.8 million in Q2 2024.
• Net loss per share was $0.23 in Q2 2025, based on 88.5 million weighted-average shares, compared to $0.24 per share on 52.4 million shares in Q2 2024.
• Cash, cash equivalents, and short-term investments totaled $173.2 million as of June 30, 2025.
• Cash usage from operations and capital equipment additions was $13.2 million in Q2 2025.
• Full-year 2025 total company revenue guidance was reduced to a range of $70 million to $80 million, down from the previous range of $80 million to $90 million.
• Full-year 2025 net loss guidance was increased to approximately $85 million, up from $83 million.
• Full-year 2025 cash usage guidance was increased to approximately $75 million, up from $47 million used in 2024.

Sentiment

Score: 4

Explanation: The sentiment is mixed to negative. While there's strong clinical adoption and positive data, the significant year-over-year revenue decline, increased net loss, and reduced full-year financial guidance, coupled with higher projected cash burn, indicate substantial financial headwinds and a challenging near-term outlook.

Positives

• Delivered 3,478 clinical tests in Q2 2025, representing a strong 59% sequential increase over Q1 2025, indicating accelerating physician adoption of the NeXT Personal platform.
• Broadened strategic collaboration with Tempus AI, Inc. to include colorectal cancer, a significant new indication, for exclusive commercialization.
• Presented pivotal data at the 2025 ASCO Annual Meeting, including results from the PREDICT and SCANDARE studies, demonstrating NeXT Personal's ability to predict therapy response in breast cancer, with nearly half of positive detections in the ultra-sensitive range.
• Additional ASCO data from the Phase 3 CALLA trial (in partnership with AstraZeneca) showed NeXT Personal detected cervical cancer progression up to 16 months earlier than standard imaging.
• Population sequencing revenue increased by 158% to $3.3 million in Q2 2025 compared to $1.3 million in Q2 2024.

Negatives

• Total revenue decreased by 24% to $17.2 million in Q2 2025 from $22.6 million in Q2 2024.
• Revenue from Natera declined by $5.6 million year-over-year.
• Revenue from pharma tests and services, and other customers decreased by 16% to $11.1 million in Q2 2025 from $13.2 million in Q2 2024.
• Gross margin decreased by 8.0% to 27.6% in Q2 2025, primarily due to lower revenue volume, customer mix, and increased unreimbursed clinical test costs.
• Net loss increased to $20.1 million in Q2 2025 from $12.8 million in Q2 2024.
• Full-year 2025 total company revenue guidance was reduced from $80-$90 million to $70-$80 million.
• Full-year 2025 revenue from pharma tests and services, and all other customers guidance was reduced from $62-$64 million to $52-$58 million due to variability with biopharma projects and timing of sample receipts.
• Full-year 2025 gross margin guidance was reduced to 22% to 24%, lower than 32% in 2024, due to investments to drive clinical use ahead of reimbursement.
• Full-year 2025 net loss guidance was increased to approximately $85 million from $83 million.
• Full-year 2025 cash usage guidance was increased to approximately $75 million, a significant rise from $47 million used in 2024, primarily due to investments in the Win-in-MRD strategy.

Risks

• Timing and pace of new orders from customers, including ModernaTX, Inc., Merck Sharp & Dohme LLC, and Natera, Inc.
• Uncertainty regarding the receipt of a task order from the U.S. Department of Veterans Affairs Million Veteran Program on the expected timeframe or amount, or at all.
• Timing of tissue, blood, and other specimen sample receipts from customers, including biopharma customers for clinical trials, which materially impacts revenue.
• Success of Personalis' clinical sales teams and Tempus' sales and marketing efforts.
• Ability to demonstrate attributes, advantages, or clinical validity of the NeXT platform, including the NeXT Personal MRD assay remaining unique in its ultra-sensitive detection capability.
• Future clinical data differing from previously presented or expected results.
• Maintaining the accelerated physician adoption rates experienced in Q2 2025.
• Reimbursement challenges for the clinical laboratory business, including establishing medical necessity and achieving cost-covering reimbursement rates.
• Failure to secure Medicare reimbursement coverage for two indications in 2025 or if coverage occurs later than expected, impacting clinical test revenue and overall revenue guidance.
• Impact of competition and macroeconomic factors on the business.
• Partnering and/or collaboration arrangements may not be successful or may terminate, adversely impacting business or ability to develop and commercialize services and products.
• Reliance on a limited number of suppliers.
• Customer concentration.

Future Outlook

The company expects total revenue for the third quarter of 2025 to be in the range of $12.0 million to $14.0 million. For the full year 2025, updated guidance projects total revenue between $70 million and $80 million (reduced from $80 million to $90 million), with pharma tests and services revenue between $52 million and $58 million (reduced from $62 million to $64 million) due to variability in biopharma projects and sample timing. Population sequencing and enterprise sales are expected to be $15 million to $16 million, and clinical tests reimbursed revenue is narrowed to $3 million to $6 million. Gross margin is projected to be 22% to 24% (lower than 32% in 2024) due to investments in clinical use. The net loss is anticipated to be approximately $85 million (increased from $83 million), with cash usage of approximately $75 million (increased from $47 million in 2024) due to investments in the Win-in-MRD strategy, including growing test volume, clinical evidence generation, and commercial capabilities. A key strategic objective for 2025 is securing Medicare coverage for two indications.

Management Comments

• "The results of our Win-in-MRD strategy are clear, with an impressive 59% sequential growth in our clinical test volume."
• "This powerful adoption trend is fueled by a continuous flow of compelling clinical data, like our recent landmark ASCO presentations, which prove the unique value of our ultra-sensitive MRD platform in guiding patient care."
• "Steady recognition and growth in the use of our platform continues to support our strategy as we navigate the temporary headwinds in the biopharma sector which have affected our current results."
• "Our fundamental growth engine is accelerating, keeping us firmly on track to achieve our most critical strategic objectives for 2025, including securing Medicare coverage for two indications."

Industry Context

The company's performance is influenced by "temporary headwinds in the biopharma sector," which have specifically impacted its pharma tests and services revenue. This suggests a broader industry trend affecting companies reliant on biopharmaceutical research and development spending. Despite these challenges, Personalis' focus on precision oncology and minimal residual disease (MRD) aligns with the growing demand for personalized cancer management and early detection, indicating a strategic positioning within a high-growth segment of the genomics and diagnostics industry.

Comparison to Industry Standards

• The filing highlights the NeXT Personal platform's unique ability to detect traces of cancer in the ultra-sensitive range, a key differentiator in the MRD market.
• Collaboration with Tempus AI, Inc. for colorectal cancer and AstraZeneca for the Phase 3 CALLA trial demonstrates partnerships with significant players in the oncology and AI sectors, indicating alignment with industry leaders.
• The company's emphasis on securing Medicare coverage for two indications reflects the critical industry challenge of achieving reimbursement for novel diagnostic tests, a common hurdle for genomics companies seeking broader market adoption.

Related Party Transactions

• Includes related party revenue of $1.9 million for the three months ended June 30, 2025, and $2.4 million for the six months ended June 30, 2025.
• Includes related party sales and marketing expenses of $0.9 million for the three months ended June 30, 2025, and $1.5 million for the six months ended June 30, 2025.
• Includes related party accounts receivable of $1.9 million as of June 30, 2025.
• Includes related party liabilities of $3.7 million (current) and $1.1 million (long-term) as of June 30, 2025.

Stakeholder Impact

• Shareholders: Negative impact due to reduced revenue guidance, increased net loss, and higher projected cash burn, potentially leading to share price depreciation. However, strong clinical adoption and strategic partnerships offer long-term potential.
• Customers (Physicians/Patients): Positive impact from accelerating adoption of the NeXT Personal platform, expanded collaboration for new indications (colorectal cancer), and compelling clinical data demonstrating earlier detection and therapy response prediction.
• Biopharma Partners: Mixed impact; while collaborations are expanding (e.g., Tempus AI, AstraZeneca), the company notes 'temporary headwinds in the biopharma sector' affecting its revenue from pharma tests and services.
• Employees: No direct impact on employment mentioned, but increased investment in the 'Win-in-MRD strategy' and commercial capabilities could imply continued focus on growth areas.

Next Steps

• Host a conference call on August 5, 2025, to discuss Q2 financial results and plans for 2025.
• Achieve most critical strategic objectives for 2025, including securing Medicare coverage for two indications.

Key Dates

Recommendation

While Personalis demonstrates strong clinical momentum with a 59% sequential increase in test volume and expanded strategic partnerships, its financial performance is deteriorating. The 24% year-over-year revenue decline, significant increase in net loss, and a substantial reduction in full-year revenue guidance, coupled with a higher projected cash burn, indicate considerable near-term headwinds. The company's long-term potential in precision oncology and MRD is promising, especially with ongoing efforts to secure Medicare reimbursement. However, the current financial challenges and increased cash usage warrant a cautious approach. A 'hold' recommendation is appropriate, balancing the strong clinical progress against the immediate financial pressures and uncertainties.

Keywords

Precision Oncology, Genomics, Minimal Residual Disease, MRD, Cancer Diagnostics, Biopharma, Clinical Tests, Next-Generation Sequencing, Personalized Medicine, Oncology, Biotechnology